In countries that have controlled classic causes of maternal death, such as eclampsia and hemorrhage, venous thromboembolism composed of pulmonary embolism and deep venous thrombosis, has become the major concern.
Several risk-scoring systems, enabling individualized estimation of thrombotic risk during pregnancy and puerperium recently have been developed but differ in their external validation, target population, risk factors and the weight of risk assigned to each risk factor.
Pregnancy is a high-risk situation for antiphospholipid syndrome patients due to the increased risk of thrombosis and obstetric complications. Recent insights, research gaps and future concepts in the pathogenesis, epidemiology, prevention, and treatment of pregnant women with antiphospholipid syndrome deserve attention. Both preeclampsia and venous thromboembolism (VTE) remains a leading cause of maternal morbidity and mortality. Personalized risk prediction for PET development and PET-associated VTE risk along with the continued refinement of PET prevention strategies are key points to decrease this morbimortality.
The postpartum period represents the most critical time for pregnancy-associated VTE. Its risk stratification and its prevention, and preferences of women for postpartum thromboprophylaxis and their adherence to treatment needs to be clarified.
Possible topics for this collection include:
1) Venous thromboembolism risk score and pregnancy.
2) Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies.
3) Preeclampsia and venous thromboembolism: pathophysiology and potential therapy.
4) Postpartum and prevention of venous thromboembolism.
5) Pulmonary embolism diagnosis and pregnancy.
6) Pulmonary embolism and pregnancy – challenges in diagnostic and therapeutic decisions.
In countries that have controlled classic causes of maternal death, such as eclampsia and hemorrhage, venous thromboembolism composed of pulmonary embolism and deep venous thrombosis, has become the major concern.
Several risk-scoring systems, enabling individualized estimation of thrombotic risk during pregnancy and puerperium recently have been developed but differ in their external validation, target population, risk factors and the weight of risk assigned to each risk factor.
Pregnancy is a high-risk situation for antiphospholipid syndrome patients due to the increased risk of thrombosis and obstetric complications. Recent insights, research gaps and future concepts in the pathogenesis, epidemiology, prevention, and treatment of pregnant women with antiphospholipid syndrome deserve attention. Both preeclampsia and venous thromboembolism (VTE) remains a leading cause of maternal morbidity and mortality. Personalized risk prediction for PET development and PET-associated VTE risk along with the continued refinement of PET prevention strategies are key points to decrease this morbimortality.
The postpartum period represents the most critical time for pregnancy-associated VTE. Its risk stratification and its prevention, and preferences of women for postpartum thromboprophylaxis and their adherence to treatment needs to be clarified.
Possible topics for this collection include:
1) Venous thromboembolism risk score and pregnancy.
2) Risk of thrombosis, pregnancy morbidity or death in antiphospholipid antibodies.
3) Preeclampsia and venous thromboembolism: pathophysiology and potential therapy.
4) Postpartum and prevention of venous thromboembolism.
5) Pulmonary embolism diagnosis and pregnancy.
6) Pulmonary embolism and pregnancy – challenges in diagnostic and therapeutic decisions.